◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Transgenic Group Inc. (2342) Financial History

Name: Transgenic Group Inc. (2342) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-10

Transgenic Group Inc. (2342) operates in the Biotechnology industry and is headquartered in Fukuoka City, Japan with about 227 employees. Its market capitalization is roughly JPY 4 billion. In the fiscal year ended 2026-03-31, 2342 reported JPY 13.2B in revenue and (JPY 77M) in net income.

Transgenic Group Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan. It operates through Drug Discovery Support Business and Investment and Consulting Business segments.

Interactive charts & full statements →

2342 Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	JPY 13.2B	JPY 13.0B	JPY 13.1B	JPY 11.4B	—
Gross Profit	JPY 2.4B	JPY 2.2B	JPY 2.2B	JPY 2.0B	—
Operating Income (EBIT)	JPY 138M	(JPY 260M)	JPY 89M	(JPY 25M)	—
Net Income	(JPY 77M)	(JPY 1.1B)	JPY 4M	(JPY 410M)	—

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2342 Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(JPY 0M)	(JPY 50M)	(JPY 84M)	(JPY 101M)	—

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2342 Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	JPY 9.7B	JPY 9.6B	JPY 9.8B	JPY 10.7B	—
Total Liabilities	JPY 4.9B	JPY 4.7B	JPY 3.8B	JPY 4.6B	—

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2342 viewer.

Other Companies in Biotechnology

VKTX · Viking Therapeutics, Inc. — $4 billion
1167 · Jacobio Pharmaceuticals Group Co., Ltd. — $4 billion
2629 · Mirxes Holding Company Limited — $4 billion
6826 · Shanghai Haohai Biological Technology Co., Ltd. — $4 billion
RCUS · Arcus Biosciences, Inc. — $4 billion
IDYA · IDEAYA Biosciences, Inc. — $4 billion
ALMS · Alumis Inc. — $4 billion
2591 · Guangzhou Innogen Pharmaceutical Group Co., Ltd — $3 billion

← 2341 All “0-9” companies 2343 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.